Q-omics provides the consensus-scored GUCA1C profile across patient tissues and cancer cell-line models. GUCA1C expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, GUCA1C is differentially expressed in 7, with the highest sampling consensus in HNSC. Additionally, GUCA1C RNA expression shows 7,977 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight BLCA, HNSC, and PDAC as cancer lineages where GUCA1C shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GUCA1C — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GUCA1C survival associations across molecular data types. GUCA1C RNA expression shows survival associations in the most cancer types (17), followed by mutation status (3) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GUCA1C RNA expression–survival associations across cancer types. High GUCA1C expression shows unfavorable associations in BLCA, READ, LUAD, KIRP, UVM and LUSC. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .005). Together, the overview and detailed table identify BLCA as the clearest survival context for GUCA1C RNA expression.
This table summarizes GUCA1C tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for GUCA1C. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GUCA1C shows lower tumor expression in KICH, KIRC, BLCA and KIRP and higher tumor expression in HNSC and COAD. The HNSC box plot shows higher GUCA1C RNA expression in tumor versus normal tissue (log2 FC = +0.168, t-test p < 0.001).
This table shows molecular features associated with GUCA1C in patient tissues and cancer cell lines. In patient samples, GUCA1C shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, GUCA1C RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Myeloma.
